How Does Platelet Dose Impact Clinical Outcomes After PRP Treatment?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-06

Study Completion Date

2022-09-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine which platelet rich plasma (PRP) injection dosage provides the most improvement in a patient's knee pain level at 26 weeks post-injection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Platelet-Rich Plasma Therapy for Patellar Tendinopathy

NCT03136965

Patellar Tendinitis

COMPLETED PHASE2

The Effect of Multiple Injection of Platlet-rich Plasma in Chronic Patellar Tendinopathy

NCT03986372

Tendinopathy

UNKNOWN PHASE2/PHASE3

Clinical Study of Pain Reduction by Peri-arthroscopic PRP Application in Knee Degeneration

NCT02189408

Knee Osteoarthritis Cartilage Damage Meniscal Tear

COMPLETED PHASE4

Plasma Injections Plus Exercise for Patellar Tendinopathy

NCT02116946

Patellar Tendinopathy

TERMINATED PHASE2

Platelet Rich Plasma in Knee Osteoarthritis

NCT05080075

Knee Osteoarthritis

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Knee osteoarthritis (OA) is a chronic progressive disease affecting more than 20% of people older than 45 years. A myriad of different treatments have been proposed in the scientific literature, and current treatment options include conservative and surgical procedures in which the main objective is to relieve pain and improve function.

Conservative nonsurgical interventions include weight management, physical therapy, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDS), corticosteroid and hyaluronic acid injections. Although these agents have been beneficial in the short term, there is a lack of evidence that such interventions alter the progression of OA. More recently, platelet-rich plasma (PRP), a biological therapy, has become an emerging treatment option to improve the status of the joint for patients with OA.

PRP is an autologous blood product that is injected into the knee joint, which contains an elevated concentration of platelets above that of whole blood. However, the optimal PRP preparation is still unknown. Studies are needed that investigate optimal platelet count and how that is related to clinical outcome.

This study is designed as a double-blind randomized controlled study, where enrolled subjects are randomized to one of five treatment groups (in blocks of 10):

1. a total PRP injection dose of less than 5 billion platelets;
2. a total PRP injection dose between 5 and \<10 billion platelets;
3. a total PRP injection dose between 10 and \<20 billion platelets;
4. a total PRP injection dose of \>20 billion platelets; and
5. a saline injection control

Each patient will be asked to complete a questionnaire at baseline, 6, 12, and 26 weeks.

After patients have completed all the study questionnaires, the Investigators will pull the results from the blood analysis, so that blood composition levels can be correlated with any pain improvements that are felt. The purpose of the study is to establish if there is a relationship between the injection dosage a patient receives and knee pain level (based on the pain scores from the self-reported questionnaire).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis, Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Intervention Type OTHER

Saline control

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 40-80 years of age
* Previous diagnosis of unilateral, primary osteoarthritis of the knee
* Knee pain; duration of symptoms \> 4 weeks
* K-L grade 0-4

Exclusion Criteria

* Under 40 years of age; over 80 years of age
* Bilateral knee pain
* Duration of symptoms \< 4 weeks
* NSAID or clopidogrel use in the last 7 days
* High risk of a thrombotic event if discontinuing NSAID or clopidogrel for four weeks.
* Steroid use in the last 6 weeks
* Active diagnosis of leukopenia/anemia/thrombocytopenia

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No